2022/05/06 ALA-1000 Received notice of patent allowance from Intellectual Property Office of India , Application No. 201947006642 Post author:alarpharm Post published:9 . 5 . 2022 Post category:Media releases You Might Also Like 2021/03/10 Breaking the Cycle of Opioid Addiction: Alar Presents Positive Interim Results of Long-acting Buprenorphine Injectable (ALA-1000) in Opioid Dependent Patients 10 . 3 . 2021 2021/04/30 ALA-1000 was granted by Intellectual Property Office of New Zealand.Patent No. 750367. 3 . 5 . 2021 2021/10/29 ALA-1000 Received notice of patent allowance from Intellectual Property Office of Vietnam, Application No. 1-2019-01258. 12 . 11 . 2021 2022/04/21 ALA-1000 Received notice of patent allowance from Intellectual Property Office of Singapore (IPOS), Application No. 11201901294Q. 21 . 4 . 2022 2022/08/10 ALA-1000 Received notice of patent allowance from National Institute of Industrial Property Institute (INAPI), Chile , Application No. 624-2019 11 . 8 . 2022
2021/03/10 Breaking the Cycle of Opioid Addiction: Alar Presents Positive Interim Results of Long-acting Buprenorphine Injectable (ALA-1000) in Opioid Dependent Patients 10 . 3 . 2021
2021/04/30 ALA-1000 was granted by Intellectual Property Office of New Zealand.Patent No. 750367. 3 . 5 . 2021
2021/10/29 ALA-1000 Received notice of patent allowance from Intellectual Property Office of Vietnam, Application No. 1-2019-01258. 12 . 11 . 2021
2022/04/21 ALA-1000 Received notice of patent allowance from Intellectual Property Office of Singapore (IPOS), Application No. 11201901294Q. 21 . 4 . 2022
2022/08/10 ALA-1000 Received notice of patent allowance from National Institute of Industrial Property Institute (INAPI), Chile , Application No. 624-2019 11 . 8 . 2022
